WallStSmart

Churchill Capital Corp XI Class A Ordinary Shares (CCXI)vsK2 Capital Acquisition Corporation Class A Ordinary Share (KTWO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

KTWO leads profitability with a 0.0% profit margin vs 0.0%. CCXI earns a higher WallStSmart Score of 32/100 (F).

CCXI

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.0

KTWO

Avoid

18

out of 100

Grade: F

Growth: 5.3Profit: 4.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
549.0%10/10

Revenue surging 549.0% year-over-year

KTWO1 strengths · Avg: 8.0/10
Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

CCXI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-47.0%2/10

ROE of -47.0% — below average capital efficiency

Free Cash FlowQuality
$-26.53M2/10

Negative free cash flow — burning cash

KTWO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.20B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.

Bull Case : KTWO

The strongest argument for KTWO centers on Price/Book.

Bear Case : CCXI

The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.

Bear Case : KTWO

The primary concerns for KTWO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

CCXI profiles as a hypergrowth stock while KTWO is a value play — different risk/reward profiles.

CCXI is growing revenue faster at 549.0% — sustainability is the question.

KTWO generates stronger free cash flow (-8M), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCXI scores higher overall (32/100 vs 18/100) and 549.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI Class A Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

K2 Capital Acquisition Corporation Class A Ordinary Share

FINANCIAL SERVICES · SHELL COMPANIES · USA

K2M Group Holdings, Inc., a medical device company, offers spinal and minimally invasive solutions in the United States and internationally.

Want to dig deeper into these stocks?